AACR and Kids Beating Cancer have announced a new grant to support pediatric leukemia research, with a particular focus on high-risk acute myeloid leukemia subtypes at the AACR Special Conference in Cancer Research: Bridging...
This year’s Party with a Purpose, hosted by the Friends of the AACR Foundation, will honor Robert H. Vonderheide, MD, DPhil, FAACR, and Andrew Rech, MD, PhD, of the University of Pennsylvania, for their...
The September Editors’ Picks from AACR's peer-reviewed journals include insights into cancer evolution in leukemia, a strategy for overcoming drug resistance, the impacts of the COVID-19 pandemic on cancer care, an investigational treatment for...
In memory of those who lost their lives or families as a result of what happened on September 11, 2001, this edition of Cancer Research Catalyst reviews the effects of the attacks and showcases...
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and some of the latest approaches that strive to overcome these hurdles. Learn about recent efforts...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.
An mRNA vaccine with immunotherapy may lower recurrence in melanoma, and active surveillance for prostate cancer has increased in the Veterans Affairs health system over the last two decades.
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More